BACKGROUND: Drug resistance is a major barrier to successful antiretroviral treatment (ART). Therefore, it is important to monitor time trends at a population level. METHODS: We included 11 084 ART-experienced patients from the Swiss HIV Cohort Study (SHCS) between 1999 and 2013. The SHCS is highly representative and includes 72% of patients receiving ART in Switzerland. Drug resistance was defined as the presence of ≥1 major mutation in a genotypic resistance test. To estimate the prevalence of drug resistance, data for patients with no resistance test was imputed based on the patient's risk of harboring drug-resistant viruses. RESULTS: The emergence of new drug resistance mutations declined dramatically from 401 to 23 patients between 1999 and 2013. The upper estimated prevalence limit of drug resistance among ART-experienced patients decreased from 57.0% in 1999 to 37.1% in 2013. The prevalence of 3-class resistance decreased from 9.0% to 4.4% and was always <0.4% for patients who initiated ART after 2006. Most patients actively participating in the SHCS in 2013 with drug-resistant viruses initiated ART before 1999 (59.8%). Nevertheless, in 2013, 94.5% of patients who initiated ART before 1999 had good remaining treatment options based on Stanford algorithm. CONCLUSIONS: Human immunodeficiency virus type 1 drug resistance among ART-experienced patients in Switzerland is a well-controlled relic from the era before combination ART. Emergence of drug resistance can be virtually stopped with new potent therapies and close monitoring.
BACKGROUND: Drug resistance is a major barrier to successful antiretroviral treatment (ART). Therefore, it is important to monitor time trends at a population level. METHODS: We included 11 084 ART-experienced patients from the Swiss HIV Cohort Study (SHCS) between 1999 and 2013. The SHCS is highly representative and includes 72% of patients receiving ART in Switzerland. Drug resistance was defined as the presence of ≥1 major mutation in a genotypic resistance test. To estimate the prevalence of drug resistance, data for patients with no resistance test was imputed based on the patient's risk of harboring drug-resistant viruses. RESULTS: The emergence of new drug resistance mutations declined dramatically from 401 to 23 patients between 1999 and 2013. The upper estimated prevalence limit of drug resistance among ART-experienced patients decreased from 57.0% in 1999 to 37.1% in 2013. The prevalence of 3-class resistance decreased from 9.0% to 4.4% and was always <0.4% for patients who initiated ART after 2006. Most patients actively participating in the SHCS in 2013 with drug-resistant viruses initiated ART before 1999 (59.8%). Nevertheless, in 2013, 94.5% of patients who initiated ART before 1999 had good remaining treatment options based on Stanford algorithm. CONCLUSIONS:Human immunodeficiency virus type 1 drug resistance among ART-experienced patients in Switzerland is a well-controlled relic from the era before combination ART. Emergence of drug resistance can be virtually stopped with new potent therapies and close monitoring.
Authors: Jessica M Fogel; Mariya V Sivay; Vanessa Cummings; Ethan A Wilson; Stephen Hart; Theresa Gamble; Oliver Laeyendecker; Reinaldo E Fernandez; Carlos Del Rio; D Scott Batey; Kenneth H Mayer; Jason E Farley; Laura McKinstry; James P Hughes; Robert H Remien; Chris Beyrer; Susan H Eshleman Journal: AIDS Date: 2020-01-01 Impact factor: 4.632
Authors: Sara Lodi; Huldrych F Günthard; John Gill; Andrew N Phillips; David Dunn; Quang Vu; Reed Siemieniuk; Federico Garcia; Roger Logan; Sophie Jose; Heiner C Bucher; Alexandra U Scherrer; Peter Reiss; Ard van Sighem; T Sonia Boender; Kholoud Porter; Richard Gilson; Dimitrios Paraskevis; Metallidis Simeon; Georgia Vourli; Santiago Moreno; Inmaculada Jarrin; Caroline Sabin; Miguel A Hernán Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.771
Authors: Shibani S Mukerji; Vikas Misra; David Lorenz; Anna M Cervantes-Arslanian; Jennifer Lyons; Spyridon Chalkias; Alysse Wurcel; Deirdre Burke; Nagagopal Venna; Susan Morgello; Igor J Koralnik; Dana Gabuzda Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Sara Lodi; Huldrych F Günthard; David Dunn; Federico Garcia; Roger Logan; Sophie Jose; Heiner C Bucher; Alexandra U Scherrer; Marie-Paule Schneider; Matthias Egger; Tracy R Glass; Peter Reiss; Ard van Sighem; T Sonia Boender; Andrew N Phillips; Kholoud Porter; David Hawkins; Santiago Moreno; Susana Monge; Dimitrios Paraskevis; Metallidis Simeon; Georgia Vourli; Caroline Sabin; Miguel A Hernán Journal: AIDS Date: 2018-01-28 Impact factor: 4.177
Authors: Huyen Nguyen; Christian Wandell Thorball; Jacques Fellay; Jürg Böni; Sabine Yerly; Matthieu Perreau; Hans H Hirsch; Katharina Kusejko; Maria Christine Thurnheer; Manuel Battegay; Matthias Cavassini; Christian R Kahlert; Enos Bernasconi; Huldrych F Günthard; Roger D Kouyos Journal: Elife Date: 2021-06-01 Impact factor: 8.140
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632